問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Radiation Therapy

Division of Obstetrics & Gynecology

Division of Hematology & Oncology

Digestive System Department

Linkou Chang Gung Medical Foundation (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

曾若涵
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

57Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾若涵

List

84Cases

2023-07-01 - 2026-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting1Sites

Terminated1Sites

2023-11-08 - 2025-05-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting4Sites

Recruiting1Sites

2022-09-01 - 2024-12-20

Phase I

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-11-18 - 2024-12-31

Phase II

Completed
An Exploratory, Randomised, Double-blind, Parallel-Group, Placebo-Controlled Phase IIa Study to Assess the Analgesic Activity of PAX-1 in Patients with Persistent Cancer Pain.

  • Condition/Disease

    Persistent Cancer Pain

  • Test Drug

    PAX-1

Participate Sites
7Sites

Recruiting2Sites

Terminated5Sites

2018-06-26 - 2030-12-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting6Sites

2024-11-01 - 2029-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

2023-03-01 - 2027-11-30

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2024-01-01 - 2030-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-06-18 - 2027-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

1 2 3 4 5 9
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB